Table 1.

Study visits and measurements

	Study visits
	Intervention period (in weeks)				Follow-up period (in weeks)		Safety follow-up (in weeks)	Unscheduled visits (in weeks)
Measurements	BL	6	12	18	24	52	104	0–52
Blood pressure	X	X	X	X	X	X		X*
Body weight	X			X		X		X*
HbA1C	X				X	X
AEs	X	X	X	X	X			X‡
AE questionnaire§				X		X	X	X*¥
I-RODS	X	X	X	X	X	X	X	X
INCAT-DS	X	X	X	X	X	X	X	X
Grip strength	X	X	X	X	X	X		X
MRC sum score	X	X	X	X	X	X		X
INCAT-SS	X	X		X		X		X*
EuroQol	X	X		X		X		X*
iMCQ		X		X		X		X*
iPCQ		X		X		X		X*
R-FSS	X	X		X		X		X*
PI-NRS	X	X		X		X		X*

Abbreviations: BL baseline, AE adverse event, I-RODS inflammatory Rasch Disability Scale, MRC Medical Research Council, INCAT-DS Inflammatory Neuropathy Cause and Treatment Disability Scale, INCAT-SS Inflammatory Neuropathy Cause and Treatment sensory sum score, iMCQ iMTA Medical Consumption Questionnaire, iPCQ iMTA Productivity Cost Questionnaire, R-FSS Rasch-built Fatigue Severity Scale, PI-NRS pain intensity numeric rating scale. *If the unscheduled visit is considered as a preliminary endpoint visit. ^§This row includes the investigator assessed (long-term) AEs investigated at weeks 52 and 104. ^‡If unscheduled visits takes place during treatment protocol, within 6 weeks of ending treatment protocol. ^¥In case of a preliminary endpoint during intervention period, week 18 AE questionnaire is completed by patient and physician